<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182533</url>
  </required_header>
  <id_info>
    <org_study_id>02-195</org_study_id>
    <nct_id>NCT00182533</nct_id>
  </id_info>
  <brief_title>Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders</brief_title>
  <official_title>Sertraline in the Treatment of Generalized Social Phobia With Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be
      effective in the treatment of generalized social phobia (GSP). However, virtually all of the
      current treatment studies with medicines, including the SSRIs, have excluded patients with
      social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering
      with primary social phobia have at least one other anxiety. This study will evaluate the
      safety and efficacy of sertraline in the treatment of generalized social phobia with
      co-occurring anxiety and mood disorders.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study drug could not be re-supplied
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression - Improvement â‰¤ 2</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Liebowitz Social Anxiety Scale [LSAS] (mean change from baseline)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Phobia Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Social Phobia Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Worry Questionnaire</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panic and Agoraphobia Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Davidson Trauma Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Anxiety Spectrum Self-Report (SHY-SR)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Phobia, Social</condition>
  <condition>Panic Disorder</condition>
  <condition>Agoraphobia</condition>
  <condition>Obsessive-Compulsive Disorder</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>25 - 200 mg/day x 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>25 - 200 mg/day x 16 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient with primary Diagnostic and Statistical Manual of Mental Disorders, 4th
             Edition (DSM-IV) GSP plus at least one of the following comorbid DSM-IV anxiety
             disorders:

               -  panic disorder with agoraphobia

               -  obsessive compulsive disorder

               -  major depressive disorder

               -  generalized anxiety disorder

          -  Score on LSAS &gt; 50

          -  Score on MADRS &lt; 25

        Exclusion Criteria:

          -  Any other primary AXIS-I diagnosis

          -  Criteria for alcohol/substance abuse/dependence

          -  History (Hx) of bipolar disorder, schizophrenia or other psychotic disorder

          -  A comorbid Axis II cluster A personality disorder

          -  Current increased risk of concomitant suicide

          -  Allergy/previous intolerance during an adequate trial (50mg/day for minimum of 4
             weeks) of sertraline

          -  Participation in any clinical trial 30 days prior to entering the study

          -  Unable to tolerate being free of/shows signs of withdrawal from benzodiazepines for 4
             weeks

          -  Hx of seizures

          -  Thyroid problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Van Ameringen, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MacAnxiety Research Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized social phobia</keyword>
  <keyword>Comorbid panic disorder with agoraphobia</keyword>
  <keyword>Comorbid obsessive compulsive disorder</keyword>
  <keyword>Comorbid generalized anxiety disorder</keyword>
  <keyword>Comorbid major depressive disorder/Dysthymia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Phobic Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
    <mesh_term>Agoraphobia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

